U.S. Luxury Stock News

Procore Technologies, Inc. ( NYSE:PCOR ) shareholders are probably feeling a little disappointed, since its shares fell...

The market has climbed 3.2% in the last 7 days and is up 31% over the last 12 months, with earnings forecast to grow by 16% annually. For those looking to invest in smaller or newer companies, penny stocks — despite their somewhat outdated name — can still offer surprising value. In this article, we highlight several penny stocks that demonstrate financial strength and have the potential for long-term growth.

Solid profit numbers didn't seem to be enough to please Asia Pacific Wire & Cable Corporation Limited's ( NASDAQ:APWC...

The United States market has shown robust growth, climbing 3.2% in the past week and an impressive 31% over the last year, with earnings projected to grow by 16% annually. In such a dynamic environment, dividend stocks that offer both reliable income and potential for capital appreciation can be particularly appealing to investors seeking stability amidst market fluctuations.

Readers hoping to buy TPG Inc. ( NASDAQ:TPG ) for its dividend will need to make their move shortly, as the stock is...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Ford Motor Company ( NYSE:F ) is about to trade ex-dividend in the next 4 days. The ex-dividend date is usually set to...

PBF Energy Inc. ( NYSE:PBF ) just released a solid earnings report, and the stock displayed some strength. However, we...

Shareholders might have noticed that Unitil Corporation ( NYSE:UTL ) filed its quarterly result this time last week...

A lackluster earnings announcement from Nordic American Tankers Limited ( NYSE:NAT ) last week didn't sink the stock...

Shareholders in Crescent Biopharma, Inc. ( NASDAQ:CBIO ) may be thrilled to learn that the analysts have just delivered...

If you are wondering whether Celcuity at US$139.44 still offers value after its run, the key question is how its fundamentals stack up against that price. The stock has moved sharply in recent periods, with returns of 17.2% over 7 days, 22.1% over 30 days, 38.7% year to date, and a very large 1 year gain accompanied by a 3 year return of 13x and a 5 year return of 4x. These moves sit against a backdrop of ongoing interest in Celcuity's role in the pharmaceuticals and biotech space. In this...

Groupon, Inc.'s (NASDAQ:GRPN) stock rose 11% last week, but insiders who sold US$97k worth of stock over the last year...

LPL Financial Holdings Inc. ( NASDAQ:LPLA ) shareholders are probably feeling a little disappointed, since its shares...

Exelixis (EXEL) opened 2026 with Q1 revenue of US$610.8 million and basic EPS of US$0.81, setting a clear marker for how the year is starting to shape up. The company has seen quarterly revenue move from US$555.4 million in Q1 2025 to US$610.8 million in Q1 2026, while basic EPS over that same span shifted from US$0.57 to US$0.81. This is prompting investors to focus on how sustained profitability and margins might influence sentiment around the latest numbers. See our full analysis for...

The Morning Bull - US Market Morning Update Thursday, May, 7 2026 E-mini S&P 500 futures are a touch higher this morning, as investors weigh easing tensions in the Middle East against fresh signs of a mixed global economy. Hopes for progress in US Iran talks have pushed oil prices lower and pulled the US 10 year Treasury yield down to around 4.35%, which can ease borrowing costs for households and companies. At the same time, US private employers added 109,000 jobs in April, the strongest...

Protagonist Therapeutics (PTGX) opened 2026 with Q1 revenue of US$56.4 million, Basic EPS of US$0.06 and net income of US$3.8 million, while trailing 12 month figures show revenue of US$74.1 million, a Basic EPS loss of US$1.79 and a net loss of US$114.7 million. Over the past year, the company has seen quarterly revenue move between US$4.7 million and US$170.6 million, alongside Basic EPS that has ranged from a US$2.11 profit to a US$0.69 loss. These figures give investors a broad set of...

Market forces rained on the parade of IDEAYA Biosciences, Inc. ( NASDAQ:IDYA ) shareholders today, when the analysts...

If you are wondering whether Powell Industries at around US$320 per share still offers value, it helps to separate headline returns from what the underlying valuation is actually saying. The stock has posted very strong returns, with gains of 26.4% over the last week, 71.5% over the past month, 172.6% year to date and 451.6% over the last year, plus a multi year return of more than 17x. Recent coverage has focused on Powell Industries as part of broader discussions around power...

It looks like OneMain Holdings, Inc. ( NYSE:OMF ) is about to go ex-dividend in the next three days. The ex-dividend...

Veeco Instruments (VECO) opened 2026 with Q1 revenue of US$158.3 million, basic EPS of roughly a US$0.01 loss, and trailing 12‑month EPS of US$0.39 on US$655.3 million of revenue, setting up a quarter where profitability was in focus. The company has seen quarterly revenue move from US$167.3 million and basic EPS of US$0.21 in Q1 2025 to US$158.3 million and a small loss in Q1 2026, while trailing 12‑month EPS moved from US$1.31 on US$717.3 million of revenue at Q4 2024 to US$0.39 on US$655.3...

Grid Dynamics Holdings, Inc. ( NASDAQ:GDYN ), might not be a large cap stock, but it saw a significant share price rise...

If you are wondering whether AAR at US$118.71 is still reasonably priced after a strong run, this article walks through what the current share price might imply about value. The stock has recent returns of 12.3% over 7 days, 4.1% over 30 days, 40.6% year to date and 101.0% over the last year, which naturally raises questions about how much upside or risk is now priced in. Recent headlines have focused on AAR's role within the broader Aerospace & Defense sector and how investors are reacting...

FDA approves an expanded label for ASCENIV to include pediatric immunodeficiency patients aged two and older. The decision allows earlier intervention for immune compromised children and broadens ASCENIV’s eligible patient pool. The approval fulfills a key post marketing commitment for ADMA Biologics and may influence future commercial uptake. For ADMA Biologics (NasdaqGM:ADMA), this regulatory milestone arrives with the stock trading at $10.08 after a very large 5 year return and a 182.4%...